Table 1.

Five loci associated with clinically-defined gout identified in the present study

SNPa	Locus	Chr	Positionb	Gene	Alleles		Trans-ethnic meta-analysis (SU)c		Association analysis (Gout)d
					Riske	Non-risk	Log10BFf	Posterior probability	OR (95%CI)	p valueg
rs2307394	2q23.1	2	148,716,428	ORC4 (ACVR2A)	C	T	6.72	0.480	1.15 (1.08, 1.24)	2.80 × 10–5
rs10994856	10q11.23	10	52,645,248	A1CF	A	G	13.23	0.024	1.31 (1.13, 1.52)	2.78 × 10–4
rs7953704	12q24.31	12	122,625,992	MLXIP	G	A	9.66	0.006	1.14 (1.06, 1.21)	2.08 × 10–4
rs2957742	15q23	15	72,302,894	MYO9A (PKM)	C	G	8.54	0.027	1.13 (1.06, 1.21)	3.54 × 10–4
rs4886755	15q24.2	15	76,298,132	NRG4	G	A	12.31	0.010	1.13 (1.05, 1.21)	6.83 × 10–4

^a dbSNP rs number

^b SNP positions are based on NCBI human genome reference sequence Build hg19

^c Results of trans-ethnic meta-analysis of SU were obtained from Ref.2 (Nakatochi, et al., Commun Biol, 2019)

^d Results of genome-wide meta-analysis of Japanese clinically-defined gout were obtained from Ref.1 (Nakayama, et al., Ann Rheum Dis, 2020)

^e Risk allele is defined as a base which increases SU level and gout risk

^f Log₁₀ (Bayes’ factor) of > 6 was adopted for a genome-wide significance level (Ref.2)

^g The significance level α was set to a p value of < 1.19 × 10^–3 (= 0.05/42 with Bonferroni correction)

Loci identified for the first time in clinically-defined gout cases are shown in bold. Of three loci, two loci including ORC4 and MYO9A were identified as novel gout loci

SNP Single nucleotide polymorphism, Chr Chromosome, SU Serum urate, BF Bayes’ factor, OR Odds ratio, 95%CI 95% Confidence interval